

Involvement of bone-marrow-derived cells in kidney fibrosis

メタデータ	言語: eng 出版者: 公開日: 2017-10-03 キーワード (Ja): キーワード (En): 作成者: メールアドレス: 所属:
URL	http://hdl.handle.net/2297/26306

Involvement of bone marrow-derived cells in kidney fibrosis

Takashi Wada^{¶#}, Norihiko Sakai^{¶*}, [#]Yoshio Sakai, Kouji Matsushima[#], Shuichi Kaneko^{*}, Kengo Furuichi^{¶*}

[¶]Division of Nephrology, [#]Department of Laboratory Medicine, ^{*}Department of Disease Control and Homeostasis, Institute of Medical, Pharmaceutical and Health Sciences, Faculty of Medicine, Kanazawa University, Kanazawa, [#]Department of Molecular Preventive Medicine, University of Tokyo, Tokyo, Japan.

Short title: Bone marrow-derived cells responsible for kidney fibrosis

Key Words: fibrocyte, chemokine, fibrosis, kidney, fibroblast, bone marrow-derived cells

Corresponding author: Takashi Wada

Division of Nephrology, Department of Laboratory Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Faculty of Medicine, Kanazawa University, Kanazawa, 13-1 Takara-machi, Kanazawa 920-8641, Japan

tel: +81-76-265-2498

fax: +81-76-234-4273

e-mail: twada@m-kanazawa.jp

Abstract

Cellular mechanisms have been proposed in the pathogenesis of fibrotic processes in kidney. In this setting, cell sources underlying the generation of matrix-producing cells in diseased kidneys have been categorized as activated resident stromal cells (e.g., fibroblasts, pericytes), infiltrating bone marrow-derived cells (e.g., fibrocytes, T cells, macrophages), cells derived from epiethelial-mesenchymal transition/endothelial-mesenchymal transition. Among these cell sources, accumulating evidence has shed light on the involvement of bone marrow-derived cells including monocytes/macrophages and a circulating mesenchymal progenitor cell, fibrocyte, in the progression of fibrosis in kidney. Bone marrow-derived cells positive for CD45 or CD34, and type I (pro)collagen dependent on chemokine system and renin-angiotensin system migrate into diseased kidneys and enhance the synthesis matrix protein, cytokines/chemokines and pro-fibrotic growth factors, which may promote and escalate chronic inflammatory processes and possible interaction with resident stromal cells, thereby perpetuating kidney fibrosis.

Introduction

Fibrosis is a characteristic hallmark that determines the prognosis of any kind of progressive kidney diseases, leading to kidney failure. The histological characteristics of interstitial fibrosis in kidney are evidenced by the presence of tubular atrophy and dilation, interstitial leukocyte infiltration, accumulation of fibroblasts, and increased interstitial matrix deposition (1). In this aspect, there is accumulating evidence that cellular mechanisms driving fibrosis are involved (2). Cell sources underlying the generation of matrix-producing cells in diseased kidneys have been categorized as follows; 1) Activated resident stromal cells (e.g., fibroblasts, pericytes), 2) infiltrating bone marrow-derived cells (e.g. fibrocytes, T cells, macrophages), 3) epithelial-mesenchymal transition, EMT/endothelial-mesenchymal transition, EndMT (3-5) (Figure 1).

Among cells responsible for kidney fibrosis, fibrocytes, originally identified as a circulating bone marrow-derived, CD34⁺ cell population of fibroblast-like cells in 1994, was reported to infiltrate from inflammatory exudates into subcutaneously implanted wound chambers (6). Accumulating evidence suggests that fibrocytes, uniquely comprising a minor fraction of the circulating pool of leukocytes (less than 1%), are a candidate for participating in organ fibrosis associated with conditions in lungs, skin and visceral fibrosis, heart, liver and kidneys, as well as in the physiological roles, such as wound repair, cochlear physiology and auditory function (7-8). In addition, a recent study reveals that the delicate balance of peroxisome proliferators-activated receptor gamma and transforming growth factor (TGF)-beta 1 activation drives the selection of an adipocyte or myofibroblast differentiation pathway through SAPK/JNK signaling (9).

Originally, fibrocytes were identified by CD34 and collagen-1 co-expression (6, 7). A recent study revealed that markers (CD45RO, 25F9, S100A8/A9) that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts (10). However, identification of markers specific to fibrocytes remains to be investigated. Fibrocytes may be identified by dual positivity of CD34 or CD45 and collagen-1 or pro-collagen-1 (6, 7).

Herein, in this manuscript, we focus on the involvement of bone marrow-derived cells, contributing to the pathogenesis of kidney fibrosis.

Detection of cells dual positive for CD34 or CD45 and type I collagen in kidney fibrosis

The detection and role of fibrocytes in the progressive fibrosis in kidney remains investigated thus far. We have uncovered CD45- and type I collagen-dual positive cells (CD45⁺/ColI⁺) infiltrated the interstitium, especially the corticomedullary regions in progressive kidney fibrosis induced by ureteral ligation in mice by immunostainings and flow cytometry analyses (11) (Figure 2a). The number of infiltrating fibrocytes increased with the progression of fibrosis after a ureteral ligation, reaching a peak on day 7 (Figure 2b). To further verify the existence of fibrocytes, dual immunostainings of CD34 and type I collagen were also performed. The infiltration of CD34- and type I collagen-dual positive cells was also observed in the interstitium and correlated with disease progression as determined by CD45- and type I collagen-dual immunostainings (11).

These findings in mice prompted us to explore the presence of CD45- and type I procollagen-dual positive cells (CD45⁺/proColI⁺) infiltrating into human kidneys, including diabetic nephropathy. The number of infiltrating CD45⁺/proColI⁺ in the interstitium correlated well with the severity of tubulointerstitial lesions, such as interstitial fibrosis, the number of CD68-positive macrophages as well as urinary monocyte chemoattractant protein-1 (MCP-1)/CCL2 levels in patients with chronic kidney disease. In particular, there was an inverse correlation between the number of interstitial CD45⁺/proColI⁺ and kidney function at the time of biopsy (12). The numbers of interstitial CD45⁺/proColI⁺ and macrophages as well as urinary MCP-1/CCL2 levels were significantly decreased during convalescence induced by glucocorticoid therapy. Collectively, these results suggest that cells dual positive for CD34 or CD45 and type I (pro)collagen may be involved in the pathogenesis of chronic kidney disease, leading to kidney fibrosis through the interaction with macrophages as well as MCP-1/CCL2.

Chemokine system involved in infiltration of bone marrow-derived cells dual positive for CD34 or CD45 and type I collagen into kidney

It is of note that fibrocytes, isolated from human and mice, express chemokine receptors such as CCR2, CCR3, CCR5, CCR7, and CXCR4, thereby regulating the recruitment to sites of fibrosis (7, 11, 13-15). Supporting this notion, intradermal instillation of SLC/CCL21 was firstly described to induce the recruitment of fibrocytes at the injected site (16). In addition to skin lesions, CCR7-expressing infiltrating cells, also positive for type 1 collagen (CCR7⁺/ColI⁺), were detected in diseased kidneys 7 days after ureteral ligation in wild-type mice (11). 37.8% of infiltrating cells expressed CCR7 (number of CCR7⁺/ColI⁺ divided by the number of CCR7⁺ or CXCR4⁺ or

CCR2⁺/ColI⁺). In wild-type mice, the ratio of CCR7⁺/ColI⁺ in obstructed kidneys was increased to 7.9% of the total isolated renal cells compared with that in normal kidneys (0.25%) and contralateral kidneys (0.21%). Of these CCR7-expressing cells in obstructed kidneys, 66.5% of cells were CXCR4⁺/CCR2⁺, 16.8% of cells were CXCR4⁺/CCR2⁻, 4.3% of cells were CXCR4⁻/CCR2⁺, and 12.4% of cells were CXCR4⁻/CCR2⁻. The impact of CCL21/CCR7 signaling on progressive kidney interstitial fibrosis was further examined. Mean interstitial fibrosis as well as the amount of hydroxyproline were reduced by almost 50 % in mice treated with anti-CCL21 antibodies compared with that in wild-type mice 7 days after an ureteral ligation, which was confirmed by the similar reduction in CCR7-null mice (11). Accordingly, based on the finding that treatment with anti-CCL21 antibodies or CCR7 deficiency resulted in over 50% reduction in the number of CD45⁺/ColI⁺, thereby CCL21/CCR7 signaling is thought to be the major pathway attracting CD45⁺/ColI⁺ into the kidney in this particular model (11). Interestingly, blockade of CCL21/CCR7 signaling reduced the number CCR2-expressing infiltrates in immunohistochemical studies along with renal transcripts of MCP-1/CCL2. *In vitro* studies also revealed that stimulation of cultured CD45⁺/ColI⁺ with angiotensin II enhanced the expression of mRNA of type 1 collagen and TGF-beta (17). These findings further suggest that CD45⁺/ColI⁺ may contribute to kidney fibrosis by producing MCP-1/CCL2 and TGF-beta, which may be responsible for chronic persistent inflammatory processes and activation of resident stromal cells (e.g., fibroblasts, pericytes) and the process to EMT/EndMT, in addition to collagen synthesis of CD45⁺/ColI⁺. All these events may orchestrates fibrotic down stream events, eventually resulting in kidney fibrosis (Figure 1).

Renin-angiotensin system and bone marrow-derived cells dual positive for CD45 and type I collagen

Renin-angiotensin system is one of the major pathway in the pathogenesis of fibrotic conditions, possibly dependent on two major distinct receptors, designated as angiotensin II type 1 receptor (ATR1) and angiotensin II type 2 receptor (ATR2). We hypothesized that CD45⁺/ColI⁺ might contribute to kidney fibrosis dependent on the renin-angiotensin system. In a murine model of kidney fibrosis, the extent of kidney fibrosis in AT2R deficient mice was more evident, concomitantly with the larger number of infiltrating CD45⁺/ColI⁺ in fibrotic kidneys (17). Interestingly, CD45⁺/ColI⁺ numbers in bone marrow were also increased in mice treated with ureteral ligation, especially in AT2R deficient mice (Figure 2c). In the points of therapeutic views, pharmacologic inhibition of AT1R reduced the degree of kidney fibrosis as well as the number of CD45⁺/ColI⁺ in both the kidney and the bone marrow. Supportingly, AT1R inhibition decreased the angiotensin II-stimulated expression of type I collagen synthesis in isolated human CD45⁺/ColI⁺, while an AT2R inhibitor augmented the expression of mRNA of type I collagen. These results suggest that AT1R/AT2R signaling may contribute to the pathogenesis of kidney fibrosis by at least two mechanisms: (1) by regulating the number of CD45⁺/ColI⁺ in bone marrow, and (2) by activation of these cells (17).

Fibrocytes: possible clinical biomarker for fibrotic disease

Clinical biomarkers for reflecting fibrogenic activity and indicating disease progression are required in various fields. Moeller et al. reported that fibrocytes defined as cells positive for CD45 and collagen-1 were significantly elevated in patients with stable

idiopathic pulmonary fibrosis (IPF), with a further increase during acute disease exacerbation. Fibrocyte numbers were an independent predictor of early mortality. The mean survival of patients with fibrocytes higher than 5% of total blood leukocytes was 7.5 months compared with 27 months for patients with less than 5%. Thus, they conclude that circulating fibrocytes in patients with IPF are an indicator for disease activity of IPF and might be useful as a clinical marker for disease progression (18). Supporting this notion, the number of interstitial CD45⁺/proColI⁺ was significantly decreased during convalescence induced by glucocorticoid therapy in patients with chronic kidney diseases (12). Further studies would be required for providing the evidence that counting fibrocyte numbers might be a biomarker for activity and progression of fibrotic conditions.

Involvement of monocytes/macrophages in kidney fibrosis

Recent studies reveal that macrophage diversity in response to their microenvironment uncovers their roles in kidney injury, raising therapeutic possibilities to attenuate kidney fibrosis (19-20). With our viewpoint, human peripheral CD14-positive monocytes/macrophages directly contribute to producing type I collagen, resulting in fibrogenesis, which are dependent on an amplification loop of MCP-1/CCL2-CCR2 (21). In addition, the presence of MCP-1/CCL2 expression is suggestive of a chronic stage of disease, especially in tubulointerstitial lesions and urinary levels of protein excretion, despite of renal etiologies through the recruitment and activation of macrophages. As is well-known, urinary protein excretion promotes and escalates tubulointerstitial lesions, resulting in kidney fibrosis. Moreover, the measurement of urinary MCP-1/CCL2 levels is a useful clinical tool for monitoring the disease activity

of inflammatory renal disorders, including diabetic nephropathy (22-25). This was supported by the fact that blockade of MCP-1/CCL2 prevented leukocyte migration to the kidney, urinary protein excretion and TGF-beta expression, thereby preventing glomerulosclerosis and interstitial fibrosis (23, 26-28). In addition to MCP-1/CCL2-CCR2, blockade of fractalkine-CX3CR1 also reduced kidney fibrosis, which was concomitant with reduction in macrophage infiltration (29). CCR2 receptor is expressed in glomerular podocytes, suggesting MCP-1/CCL2 activation of CCR2 on podocytes may underlie induction of MMP-12, leading to glomerular basement membrane damage and urinary protein excretion (30). Finally, it is of note that there were significant correlations between the numbers of CD45⁺/proColI⁺ and macrophages in human kidneys as well as urinary levels of MCP-1/CCL2, suggesting the close relationship of CD45⁺/proColI⁺ with macrophages. Based on these results, we propose MCP-1/CCL2-CCR2 axis on the recruitment and activation of bone marrow-derived cells, especially macrophages, play a role in the pathogenesis of tubulointerstitial lesions, resulting in kidney fibrosis despite of kidney etiologies (Figure 3).

Involvement of T cells in kidney fibrosis

The degree of fibrosis is related to leukocyte infiltration. Tapmeier et al. examined the role of different T cell populations on kidney fibrosis in the mouse model of unilateral ureteral obstruction (31). They found a critical role for CD4⁺ T cells in kidney fibrosis. In addition, Nikolic-Paterson describes modulation of T cells in the process of kidney fibrosis; 1) T cells may act directly fibroblasts and pericytes to promote their migration, proliferation, and differentiation, resulting in the accumulation of alpha-SMA⁺ myofibroblasts, which synthesize and deposit interstitial matrix, 2) T cells may induce a

profibrotic phenotype in the infiltrating macrophage population, which, in turn, secrete pro-fibrotic and pro-proliferative cytokines and growth factors that induce fibroblast migration, proliferation, and differentiation, 3) T cells may act directly on tubular epithelial cells to induce secretion of cytokines and growth factors that, in turn, act on fibroblasts (32).

Stromal cell activation and myofibroblast generation in kidney fibrosis

Activation of local stromal cells (e.g., fibroblasts and pericytes) and generation of myofibroblasts from epithelial cells (via EMT), pericytes, endothelial cells (via EndMT) and bone marrow-derived cells are key processes in tubulointerstitial fibrosis (33). For 15 years, EMT has been viewed as a principle source of fibroblasts in tissue fibrosis (34). In addition to tubular epithelial cells, glomerular podocytes (35) and endothelial cells (36-37) undergo transition after injury, which have been reported to be involved in kidney damage, resulting in fibrosis. More recently, in the process of perpetuation of fibrogenesis, hypermethylation of *RASAL1*, encoding an inhibitor of the Ras oncoprotein, is associated with the perpetuation of fibroblast activation and fibrogenesis in the kidney (38). In contrast, Duffiels et al. describe that pericytes and perivascular fibroblasts are primary source of collagen-producing cells in kidney fibrosis (39-40). Therefore, further studies would be required for determining the degree to which processes including those resulted from bone marrow-derived cells, contributes to kidney fibrosis.

Concluding remarks and future directions

A deep insight of bone marrow-derived cells dependent on chemokine system and renin-angiotensin system provides a key for the novel pathogenesis of progressive organ fibrosis including kidney fibrosis. In addition to those systems, our recent unpublished data suggest the possible involvement of CD45⁺/ColI⁺ in diabetic nephropathy, which is supported by the evidence that CD45⁺/proColI⁺ are detected in human diabetic nephropathy (12). Further studies for biology of bone marrow-derived cells and the interaction of resident stromal cells would be required for a better understanding and the therapeutic benefit for kidney fibrosis.

Acknowledgements

TW is a recipient of a Grant-in-Aid from the Ministry of Education, Science, Sports and Culture in Japan and Takeda Science Foundation.

References

1. Strutz F, Zeisberg M. Renal fibroblasts and myofibroblasts in chronic kidney disease. *J Am Soc Nephrol*. 2006; 17, 2992-2998.
2. Wynn TA. Cellular and molecular mechanisms of fibrosis. *J Pathol*. 2008; 214, 199-210.
3. Guarino M, Tosoni A, Nebuloni M. Direct contribution of epithelium to organ fibrosis: epithelial-mesenchymal transition. *Hum Pathol* 2009; 40, 1365-1376.
4. Vernon MA, Mylonas K, Hughes J. Macrophages and renal fibrosis. *Semin Nephrol*. 2010; 30, 302-307.

5. Tapmeier TT, Fearn A, Brown K, Chowdhury P, Sacks SH, Sheerin NS, Wong W. Pivotal role of CD4⁺ T cells in renal fibrosis following ureteric obstruction. *Kidney Int.* 2010; 78, 351-362.
6. Bucala R, Spiegel L, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. *Mol Med* 1994; 1, 71-81.
7. Herzog EL, Bucala R. Fibrocytes in health and disease. *Exp Hematol.* 2010; 38, 548-556.
8. Delprat B, Ruel J, Guitton MJ, Hamard G, Lenior M, Pujol R, Puel JL, Brabet P, Hamel CP. Deafness and cochlear fibrocyte alterations in mice deficient for the inner ear protein otospiralin. *Mol Cell Biol.* 2005; 25, 847-853.
9. Hong KM, Belperio JA, Keane MP, Burdick MD, Strieter RM. Differentiation of human circulating fibrocytes as mediated by transforming growth factor-beta and peroxisome proliferators-activated receptor gamma. *J Biol Chem.* 2007; 282, 22910-22920.
10. Pilling D, Fan T, Huang D, Kaul B, Gomer RH. Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. *PLoS One* 2009; 4, e7475.
11. Sakai N, Wada T, Yokoyama H, Lipps M, Ueha S, Matsushima K, Kaneko S. Secondary lymphoid tissue chemokine (SLC/CCL21)/CCR7 signaling regulates fibrocytes in renal fibrosis. *Proc Natl Acad Sci USA.* 2006; 103, 14098-14103.
12. Sakai N, Furuichi K, Shinozaki Y, Yamauchi H, Toyama T, Kitajima S, Okumura T, Kokubo S, Kobayashi M, Takasawa K, Takeda S, Yoshimura M, Kaneko S, Wada T. Fibrocytes are involved in the pathogenesis of human chronic kidney disease. *Human Pathol.* 2010; 41, 672-678.

13. Moore BB, Kolodsick JE, Thannickal VJ, Cooke K, Moore TA, Hogaboam C, Wilke CA, Toews GB. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. *Am J Pathol.* 2005; 166, 675-684.
14. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, Belperio JA, Keane MP, Strieter RM. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. *J Clin Invest.* 2004; 114, 438-446.
15. Ishida Y, Kimura A, Kondo T, Hayashi T, Ueno M, Takakura N, Matsushima K, Mukaida N. Essential roles of the CC chemokine ligand 3-CC chemokine receptor 5 axis in bleomycin-induced pulmonary fibrosis through regulation of macrophage and fibrocyte infiltration. *Am J Pathol.* 2007; 170, 843-854.
16. Abe R, Donnelly SC, Peng T, Bulaca R, Metz CN. Peripheral blood fibrocytes: Differentiation pathway and migration to wound sites. *J Immunol.* 2001; 166: 7556-7562.
17. Sakai N, Wada T, Iwai M, Horiuchi M, Matsushima K, Kaneko S. The renin-angiotensin system contributes to renal fibrosis through regulation of fibrocytes. *J Hypertens.* 2008; 26, 780-790.
18. Moeller A, Gilpin SE, Ask K, Cox G, Cook D, Gauldie J, Margetts PJ, Farkas L, Dobranowski J, Boylan C, O'Byrne PM, Strieter RM, Kolb M. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med.* 2009; 79, 588-594.
19. Ricardo SD, van Goor H, Eddy AA. Macrophage diversity in renal injury and repair. *J Clin Invest.* 2008;118, 3522-3530.
20. Ninichuk V, Anders HJ. Bone marrow-derived progenitor cells and renal fibrosis. *Front Biosci.* 2008; 13, 5163-5167.

21. Sakai N, Wada T, Furuichi K, Shimizu K, Kokubo S, Hara A, Yamahana J, Okumura T, Matsushima K, Yokoyama H, Kaneko S. MCP-1/CCR2-dependent loop for fibrogenesis in human peripheral CD14-positive monocytes. *J Leukoc Biol.* 2006; 79, 555-563.
22. Wada T, Yokoyama H, Su SB, Mukaida N, Iwano M, Dohi K, Takahashi Y, Sasaki T, Furuichi K, Segawa, C, Hisada Y, Ohta S, Takasawa K, Kobayashi K, Matsushima K. Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. *Kidney Int.* 1996; 49, 761-767.
23. Wada T, Yokoyama H, Furuichi K, Kobayashi K, Harada K, Naruto M, Su SB, Akiyama, M, Mukaida N, Matsushima. Intervention of crescentic glomerulonephritis by antibodies to monocyte chemotactic and activating factor (MCAF/MCP-1). *FASEB J.* 1996; 10, 1418-1425.
24. Wada T, Furuichi K, Segawa C, Shimizu M, Sakai N, Takeda S, Takasawa K, Kida H, Kobayashi, K, Mukaida N, Ohmoto Y, Matsushima K, Yokoyama H. MIP-1 α and MCP-1 contribute crescents and interstitial lesions in human crescentic glomerulonephritis. *Kidney Int.* 1999; 56, 995-1003.
25. Wada T, Furuichi K, Sakai N, Iwata Y, Yoshimoto K, Shimizu M, Takeda S, Takasawa K, Yoshimura M, Kida H, Kobayashi KI, Mukaida N, Naito T, Matsushima K, Yokoyama H. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. *Kidney Int* 2000; 58, 1492-1498.

26. Wu X, Dolecki GJ, Sherry B, Zagorski J, Lefkowitz JB. Chemokines are expressed in a myeloid cell-dependent fashion and mediate distinct functions in immune complex glomerulonephritis in rat. *J Immunol.* 1997; 158,3917-3924.
27. Wada T, Furuichi K, Sakai N, Iwata Y, Kitagawa K, Ishida Y, Kondo T, Hashimoto H, Ishiwata Y, Mukaida N, Tomosugi N, Matsushima K, Egashira K, Yokoyama H. Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. *J Am Soc Nephrol.* 2004;15, 940-948.
28. Kitagawa K, Wada T, Furuichi K, Hashimoto H, Ishiwata Y, Asano M, Takeya M, Kuziel WA, Matsushima K, Mukaida N, Yokoyama H. Blockade of CCR2 ameliorates progressive fibrosis in kidney. *Am J Pathol.* 2004;165, 237-246.
29. Furuichi K, Gao JL, Murphy PM. Chemokine receptor CX3CR1 regulates renal interstitial fibrosis after ischemia-reperfusion injury. *Am J Pathol.* 2006;169, 372-387.
30. Rao VH, Meehan DT, Delimont D, Nakajima M, Wada T, Gratton MA, Cosgrove D. Role for macrophage metalloelastase in glomerular basement membrane damage associated with alport syndrome. *Am J Pathol.* 2006;169, 32-46.
31. Tapmeier TT, Fearn A, Brown K, Chowdhury P, Sacks SH, Sheerin NS, Wong W. Pivotal role of CD4⁺ T cells in renal fibrosis following ureteric obstruction. *Kidney Int.* 2010;78, 351-362.
32. Nikolic-Paterson DJ. CD4⁺ T cells: a potential player in renal fibrosis. *Kidney Int.* 2010;78, 333-335.
33. Grande MT, López-Novoa JM. Fibroblast activation and myofibroblast generation in obstructive nephropathy. *Nat Rev Nephrol.* 2009;5, 319-328.
34. Zeisberg M, Duffield JS. Resolved: EMT produces fibroblasts in the kidney. *J Am Soc Nephrol.* 2010;21, 1247-1253.

35. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. *J Am Soc Nephrol.* 2010; 21, 212-222.
36. Li J, Qu X, Bertram JF. Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice. *Am J Pathol.* 2009;175, 1380-1388.
37. Kizu A, Medici D, Kalluri R. Endothelial-mesenchymal transition as a novel mechanism for generating myofibroblasts during diabetic nephropathy. *Am J Pathol.* 2009; 175, 371-373.
38. Bechtel W, McGookan S, Zeisberg EM, Müller GA, Kalbacher H, Salant DJ, Müller CA, Kalluri R, Zeisberg M. Methylation determines fibroblast activation and fibrogenesis in the kidney. *Nat Med.* 2010;16, 544-550.
39. Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, Bonventre JV, Valerius MT, McMahon AP, Duffield JS. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. *Am J Pathol.* 2010;176, 85-97.
40. Lin SL, Kisseleva T, Brenner DA, Duffield JS. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. *Am J Pathol.* 2008;173, 1617-1627.

Figure legends

Figure 1. Possible cellular mechanisms involved in fibrosis in kidney

Figure 2. Cells dual positive for CD34 or CD45 and type I collagen, detected in kidneys and bone marrow, may play a role in kidney fibrosis.

(a) In wild-type mice, CD45⁺/ColI⁺ infiltrated the Interstitium, especially the corticomedullary regions after ureteral ligation. (b) The number of infiltrating CD45⁺/ColI⁺ as well as mean interstitial fibrosis in kidney were reduced in mice treated with anti-CCL21 antibodies and in CCR7-null mice compared with that in wild-type mice 7 days after ureteral ligation. Values are the mean $\pm$ SEM. (c) By flow cytometry analyses, fibrocytes increased in number at bone marrow cells, which was enhanced in AT2R-null mice with ureteral ligation.

Figure 3. Macrophages dependent on MCP-1/CCL2-CCR2 axis contribute to progressive kidney diseases, resulting in fibrosis.